Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide in Asian Stage III NSCLC
NCT01015443Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Dec 2009
- Primary completion
- Jun 2015
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of tecemotide in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Dec 2009; status: terminated.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01015443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01015443.